Earnings results for Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is expected* to report earnings on 05/05/2021 after market close. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.69. The reported EPS for the same quarter last year was $-0.84.
Aerie Pharmaceuticals last announced its quarterly earnings data on February 25th, 2021. The reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The business earned $24.68 million during the quarter, compared to analysts’ expectations of $21.75 million. Aerie Pharmaceuticals has generated ($3.40) earnings per share over the last year. Aerie Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Wednesday, May 5th, 2021. Aerie Pharmaceuticals will be holding an earnings conference call on Wednesday, May 5th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Aerie Pharmaceuticals (NASDAQ:AERI)
10 Wall Street analysts have issued ratings and price targets for Aerie Pharmaceuticals in the last 12 months. Their average twelve-month price target is $23.89, predicting that the stock has a possible upside of 38.17%. The high price target for AERI is $32.00 and the low price target for AERI is $9.00. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Aerie Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating. According to analysts’ consensus price target of $23.89, Aerie Pharmaceuticals has a forecasted upside of 38.2% from its current price of $17.29. Aerie Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals does not currently pay a dividend. Aerie Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Aerie Pharmaceuticals (NASDAQ:AERI)
In the past three months, Aerie Pharmaceuticals insiders have not sold or bought any company stock. Only 9.72% of the stock of Aerie Pharmaceuticals is held by insiders. 99.89% of the stock of Aerie Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Aerie Pharmaceuticals (NASDAQ:AERI
Earnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($3.76) to ($2.49) per share. The P/E ratio of Aerie Pharmaceuticals is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Aerie Pharmaceuticals is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Aerie Pharmaceuticals has a P/B Ratio of 4.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here